Transcranial Magnetic Stimulation Reduces PTSD Symptoms in Clinical Cohort

A retrospective study of 127 patients found that 65.4% achieved a clinically meaningful reduction in PCL-5 scores following rTMS treatment.

For Doctors in a Hurry

Clinicians lack robust data regarding the efficacy of repetitive transcranial magnetic stimulation for treating patients with post-traumatic stress disorder.
The researchers conducted a retrospective analysis of 127 patients who underwent standardized dorsolateral prefrontal cortex stimulation between 2021 and 2023.
Mean symptom scores decreased from 49.55 to 29.07, with 65.4 percent of patients achieving a clinically meaningful response (p < 0.0001).
The authors conclude that this stimulation protocol effectively reduces symptom severity in patients with post-traumatic stress disorder without severe adverse events.
Physicians may consider this well-tolerated intervention, though future research must determine long-term symptom stability and optimal stimulation parameters for patients.

Neuromodulation for Treatment-Resistant Post-Traumatic Stress

Post-traumatic stress disorder remains a significant clinical challenge, often proving refractory to standard pharmacotherapy and psychological interventions [1, 2]. While fronto-limbic circuit dysfunction is a known hallmark of the condition, traditional treatments frequently yield only modest efficacy in achieving full remission [3, 4]. Neuromodulation techniques, specifically repetitive transcranial magnetic stimulation (a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain), have emerged as a strategy to modulate cortical activity and address these underlying neurobiological deficits [5, 6]. However, clinicians still face uncertainty regarding the magnitude of expected symptom improvement and the consistency of response across diverse patient populations [7, 8]. A recent retrospective analysis provides data on the efficacy of this intervention in a large clinical cohort.

Cohort Characteristics and Inclusion Criteria

The researchers conducted a retrospective analysis of 127 patients who received treatment between December 2021 and December 2023. This clinical cohort consisted of individuals who underwent a standardized repetitive transcranial magnetic stimulation protocol, a procedure that utilizes magnetic fields to induce electrical activity in specific cortical regions. By reviewing records from this two year period, the study aimed to quantify the real world effectiveness of the intervention in a population that met the formal diagnostic criteria for post-traumatic stress disorder. To ensure a standardized assessment of symptom severity, the study utilized the PTSD Checklist for DSM-5 (PCL-5), which is a 20 item self report instrument that measures the core symptoms of the disorder, such as intrusion, avoidance, and hyperarousal. Inclusion in the analysis required a baseline PCL-5 score of 31 or higher, a threshold commonly used to indicate a probable diagnosis and a level of symptom burden that warrants clinical intervention. This specific cutoff ensured that the study population represented patients with clinically significant psychiatric and functional impairments rather than those with subclinical distress. The cohort entered the treatment protocol with a mean pre-treatment PCL-5 score of 49.55, reflecting a high level of baseline symptom severity. For clinicians, this score indicates a population experiencing substantial distress, as it sits nearly 20 points above the minimum diagnostic threshold. By establishing this baseline, the researchers were able to use paired t-tests (a statistical method used to determine if there is a significant difference between the means of two related groups) to precisely measure the magnitude of symptom reduction following the completion of the stimulation sessions.

Standardized Stimulation Parameters

The therapeutic protocol utilized in this study was administered to the patient cohort between December 2021 and December 2023. During this two year window, clinicians employed a standardized repetitive transcranial magnetic stimulation approach designed to modulate specific neural circuits implicated in post-traumatic stress. The primary neuroanatomical target for all 127 patients was the dorsolateral prefrontal cortex, a region frequently associated with executive function and the top-down regulation of emotional responses. In patients with post-traumatic stress disorder, this area often shows diminished activity, leading to an inability to inhibit the overactive fear centers of the brain. By focusing magnetic pulses on this area, the treatment aims to address the underlying neurobiological dysregulation that characterizes the disorder. To ensure the safety and precision of the intervention, the researchers utilized individualized motor threshold mapping for each patient. This technique involves a systematic calibration process to determine the minimum magnetic field strength required to elicit a visible muscle twitch in the patient's hand. By establishing this personal baseline, clinicians can precisely calculate the specific dosage of magnetic energy needed to reach the cortical tissue effectively without exceeding safety limits. This individualized calibration is a critical step in the protocol, as it accounts for anatomical variations in skull thickness and brain morphology, ensuring that the stimulation intensity is optimized for each individual's unique physiology.

Quantifying Symptom Reduction and Clinical Response

The researchers evaluated the efficacy of the intervention by comparing symptom severity before and after the treatment course using the PTSD Checklist for DSM-5 (PCL-5). To quantify these changes, PCL-5 scores were assessed pre-treatment and post-treatment using paired t-tests. The analysis revealed that the mean post-treatment PCL-5 score decreased to 29.07, representing a substantial decline from the baseline mean of 49.55. This reduction in symptom burden was statistically significant with a p-value of less than 0.0001, indicating a high degree of confidence that the observed changes were not due to chance. To determine the practical utility of the treatment for practicing clinicians, the study established specific benchmarks for therapeutic success. A clinically meaningful response was defined as a 30% or greater reduction in PCL-5 score from the initial baseline. According to this metric, 65.4% of patients achieved a clinically meaningful response, suggesting that nearly two-thirds of the cohort experienced a significant easing of their psychiatric burden. Furthermore, the researchers identified a subset of high responders, finding that 42.5% of patients achieved a 50% or greater reduction in PCL-5 scores, which often corresponds to a transition from severe functional impairment to sub-threshold symptom levels. Based on these quantitative outcomes, the researchers concluded that repetitive transcranial magnetic stimulation significantly reduces symptom severity and is a well-tolerated intervention. Because the post-treatment mean score of 29.07 fell below the study's inclusion threshold of 31, the data suggests that a majority of patients moved toward clinical remission. These findings provide evidence that targeted neuromodulation can produce robust, statistically significant improvements in a clinical population, offering a viable alternative for patients who may not have achieved adequate relief through traditional pharmacotherapy or psychotherapy.

Safety Profile and Sex-Based Response Variations

For clinicians evaluating the feasibility of neuromodulation in an outpatient setting, the safety profile of the intervention is as critical as its efficacy. In this retrospective analysis of 127 patients, the researchers reported that the standardized protocol was well-tolerated across the cohort. Most notably, no severe adverse events, specifically including seizures, were reported during the study. The absence of seizures is a significant finding for practicing physicians, as this remains the primary safety concern associated with repetitive transcranial magnetic stimulation. These results suggest that the individualized motor threshold mapping effectively mitigated the risks typically associated with high-frequency stimulation of the dorsolateral prefrontal cortex. The data also revealed distinct differences in how patients responded to treatment based on biological sex, which may assist clinicians in managing patient expectations and refining prognosis. While both groups experienced substantial clinical improvement, female patients demonstrated a 41.57% reduction in PTSD symptom severity, whereas male patients demonstrated a 36.64% reduction. This variance suggests that while the intervention is effective for both sexes, biological factors may influence the magnitude of the therapeutic response. The clinical relevance of these findings is underscored by the broad impact of the condition, as post-traumatic stress disorder affects approximately 7% of the United States population. Beyond the diagnostic criteria, the disorder can result in significant psychiatric and functional impairments, often leading to a total disruption of social and occupational life. By achieving a mean reduction in PCL-5 scores from 49.55 to 29.07, this intervention addresses a critical need for the millions of Americans suffering from the long-term sequelae of trauma. The study concludes that repetitive transcranial magnetic stimulation provides a safe and effective alternative for reducing the psychiatric burden in this high-prevalence population.

Study Info

Retrospective single-arm pre-post interventional study demonstrates reduction in PCL-5 scores with repetitive transcranial magnetic stimulation

Joslyn Johnson, Pia Arellano, Ana M. Chang, Jorge A. Hernández, et al.

Journal Journal of Affective Disorders

Published December 16, 2025